产品
编 号：F131132
分子式：C24H42N2OS3
分子量：470.8
分子式：C24H42N2OS3
分子量：470.8
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
结构图
CAS No: 135025-12-6
产品详情
生物活性：
CP-113818 is a potent cholesterol acyltransferase (ACAT) inhibitor. CP-113818 can be used for the research of Alzheimer's disease.
体内研究：
CP-113818 (0-7.1 mg/kg/day) markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.Animal Model:C57BL/6, hAPP (human amyloid precursor protein) transgenic mice
Dosage:0, 0.2, 1.6, 3.2, 4.8, and 7.1 mg/kg/day
Administration:Via implantable slow-release biopolymer pellets, 21 days for nontransgenic mice or 60 days for hAPP mice
Result:Reduced total cholesterol levels by 29% in the serum, hepatic free cholesterol and cholesteryl-esters were also decreased in a dose-dependent manner by up to 37% and 93%, respectively in the nontransgenic mice. Effectively reduced cholesteryl-ester levels of hAPP mice in the absence of adrenal toxicity, reduced plaque numbers, and decreased amyloid load in a gender-independent manner in hAPP mice. Reduced levels of “insoluble” and soluble Aβ1-40 and Aβ1-42 in the brains of hAPP transgenic mice. Restored normal spatial learning and memory in female hAPP mice in a morris water maze test. Reduced processing of endogenous APP but not notch or N-cadherin, without directly inhibiting β- and γ-secretase activities or Aβ aggregation in nontransgenic littermates.
体外研究：
CP-113818 inhibits Aβ production in cell-based experiments.
CP-113818 is a potent cholesterol acyltransferase (ACAT) inhibitor. CP-113818 can be used for the research of Alzheimer's disease.
体内研究：
CP-113818 (0-7.1 mg/kg/day) markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.Animal Model:C57BL/6, hAPP (human amyloid precursor protein) transgenic mice
Dosage:0, 0.2, 1.6, 3.2, 4.8, and 7.1 mg/kg/day
Administration:Via implantable slow-release biopolymer pellets, 21 days for nontransgenic mice or 60 days for hAPP mice
Result:Reduced total cholesterol levels by 29% in the serum, hepatic free cholesterol and cholesteryl-esters were also decreased in a dose-dependent manner by up to 37% and 93%, respectively in the nontransgenic mice. Effectively reduced cholesteryl-ester levels of hAPP mice in the absence of adrenal toxicity, reduced plaque numbers, and decreased amyloid load in a gender-independent manner in hAPP mice. Reduced levels of “insoluble” and soluble Aβ1-40 and Aβ1-42 in the brains of hAPP transgenic mice. Restored normal spatial learning and memory in female hAPP mice in a morris water maze test. Reduced processing of endogenous APP but not notch or N-cadherin, without directly inhibiting β- and γ-secretase activities or Aβ aggregation in nontransgenic littermates.
体外研究：
CP-113818 inhibits Aβ production in cell-based experiments.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备